Cinitapride monotartrate

Cat. No.: HY-128386

CAS No.: 1207859-16-2

Molecular Formula: $C_{25}H_{36}N_4O_{10}$

Molecular Weight: 552.57

Target: Dopamine Receptor; 5-HT Receptor

Pathway: GPCR/G Protein; Neuronal Signaling

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

Cinitapride monotartrate is a 5-HT_{1A} and 5-HT_4 agonist. Cinitapride monotartrate is also a 5-HT_{2A} and D_2 antagonist. Cinitapride monotartrate can be used for the research of functional dyspepsia[1][2].

IC_{50} & Target	5-HT_2 Receptor	5-HT_1 Receptor	5-HT_4 Receptor	D_2 Receptor

In Vivo

Cinitapride (intraperitoneal injection; 0.25-1 mg/kg; once) shows gastroprotective effetcs in gastric ulceration rat model[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Wistar rats with gastric ulceration[2]
Dosage:	0.25-1 mg/kg
Administration:	Intraperitoneal injection; 0.25-1 mg/kg; once
Result:	Reduced haemorrhagic lesions compared with the ulcerated control group. Decreased the percentage of ulceration to 28.76% at the highest dose (1 mg/kg). Attenuated the increase myeloperoxidase activity ($p<0.05$, $p<0.01$). Increased GSH-px activity in the gastric mucosa.

REFERENCES

[1]. Du Y, et al. Efficacy and safety of cinitapride in the treatment of mild to moderate postprandial distress syndrome-predominant functional dyspepsia. J Clin Gastroenterol. 2014 Apr;48(4):328-35.

[2]. Alarcón de la Lastra C, et al. Effects of cinitapride on gastric ulceration and secretion in rats. Inflamm Res. 1998 Mar;47(3):131-6.

[3]. Parthena MARTIN, et al. Compositions and methods for treating seizure disorders. Patent WO2018060732A2.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA